Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

KZIA

Kazia Therapeutics Limited ADR

Apr 15 • 04:00PM ET

0.3070

Dollar change -0.0490
Percentage change -13.76	%

Healthcare • Biotechnology • Australia • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.44	Insider Own	-	Shs Outstand	23.63M	Perf Week	-24.20%
Market Cap	7.25M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	23.62M	Perf Month	37.42%
Income	-10.40M	PEG	-	EPS next Q	-	Inst Own	20.66%	Short Float	1.10%	Perf Quarter	-12.26%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	25.42%	Short Ratio	0.29	Perf Half Y	-58.79%
Book/sh	0.14	P/B	2.25	EPS next Y	-	ROA	-58.59%	Short Interest	0.26M	Perf Year	-71.83%
Cash/sh	0.10	P/C	2.99	EPS next 5Y	-	ROE	-181.74%	52W Range	0.19 - 1.68	Perf YTD	-30.15%
Dividend Est.	-	P/FCF	-	EPS past 5Y	4.22%	ROI	-289.47%	52W High	-81.73%	Beta	2.10
Dividend TTM	-	Quick Ratio	0.71	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	64.52%	ATR (14)	0.05
Dividend Ex-Date	-	Current Ratio	0.71	EPS Y/Y TTM	64.58%	Oper. Margin	0.00%	RSI (14)	47.25	Volatility	22.55% 15.55%
Employees	-	Debt/Eq	0.07	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	2.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	61.57%	Payout	-	Rel Volume	0.51	Prev Close	0.36
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	885.59K	Price	0.31
SMA20	-4.31%	SMA50	6.09%	SMA200	-51.20%	Trades		Volume	456,170	Change	-13.76%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-14-21	Initiated	Maxim Group	Buy	$18
Jan-05-21	Initiated	H.C. Wainwright	Buy	$17

Mar-24-24 07:55AM	11 Best ASX Stocks To Buy Now (Insider Monkey)
Mar-21-24 08:52AM	Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases (PR Newswire) -8.89%
Mar-13-24 08:00AM	Kazia announces presentation of new data at AACR Annual Meeting (PR Newswire) +8.36%
Feb-21-24 07:30AM	Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint (PR Newswire) -20.61%
Jan-18-24 07:30AM	KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS (PR Newswire)
06:02PM	Loading…
Dec-05-23 06:02PM	Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering (PR Newswire)
Dec-01-23 08:00AM	Kazia Therapeutics Announces $2 Million Registered Direct Offering (PR Newswire) -19.56%
Nov-29-23 07:01AM	KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY (PR Newswire) -6.34%
Nov-21-23 07:30AM	KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING (PR Newswire) -10.59%
Nov-20-23 04:30PM	KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION (PR Newswire) -6.11%
Nov-15-23 08:30AM	KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING (PR Newswire)
Nov-10-23 07:01AM	KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMA (PR Newswire)
Nov-01-23 07:01AM	KAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING PHASE 2 STUDY OF PAXALISIB IN PRIMARY CNS LYMPHOMA (PR Newswire)
Oct-23-23 07:01AM	KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY (PR Newswire) -5.29%
Oct-11-23 07:01AM	Kazia announces voluntary delisting from ASX (PR Newswire) -15.78%
07:01AM	Loading…
Oct-05-23 07:01AM	KAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING SCIENTIFIC MEETINGS (PR Newswire)
Sep-29-23 07:01AM	KAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT AND ORAL PRESENTATION OF PNOC022 CLINICAL DATA AT 2023 SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING (PR Newswire) -5.21%
Jul-06-23 07:00AM	KAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA FOR TREATMENT OF SOLID TUMOR BRAIN METASTASES HARBORING PI3K PATHWAY MUTATIONS IN COMBINATION WITH RADIATION THERAPY (PR Newswire) -8.55%
Jun-08-23 07:00AM	KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA (PR Newswire)
May-25-23 07:01AM	KAZIA CEO, DR. JOHN FRIEND TO PARTICIPATE IN WHITE HOUSE CANCER MOONSHOT (PR Newswire)
Apr-14-23 07:01AM	KAZIA REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT (PR Newswire) +9.09%
Apr-04-23 07:00AM	KAZIA PRESENTS NEW DATA FOR PAXALISIB AND EVT801 AT AACR ANNUAL MEETING (PR Newswire) +6.86%
Jan-25-23 03:03PM	Trade Alert: Stephen Abolakian At Kazia Therapeutics Limited (ASX:KZA), Has Just Spent AU$1m Buying 54% More Shares (Simply Wall St.) -5.81%
Jan-18-23 11:50AM	Kazia Therapeutics CEO talks $4.5 million capital raise (News Direct) +5.28%
Jan-16-23 07:01AM	KAZIA RAISES A$4.5 MILLION TO PROGRESS R&D PROGRAMS (PR Newswire)
Dec-19-22 09:00PM	Kazia Therapeutics (KZIA): Collaboration May Expand Utility to Combo Therapies (ACCESSWIRE)
Dec-15-22 07:01AM	KAZIA LAUNCHES PRECLINICAL COLLABORATION WITH QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE AND ANNOUNCES PATENT FILING (PR Newswire)
Dec-12-22 07:01AM	KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION (PR Newswire)
Dec-01-22 07:01AM	COMPELLING PRECLINICAL DATA FOR KAZIA'S EVT801 PUBLISHED IN PEER-REVIEWED CANCER RESEARCH JOURNAL (PR Newswire) +5.20%
Nov-28-22 04:50PM	Quite a few insiders invested in Kazia Therapeutics Limited (ASX:KZA) last year which is positive news for shareholders (Simply Wall St.)
07:00AM	Loading…
Nov-09-22 07:00AM	KAZIA TO PRESENT PAXALISIB DATA IN ADULT AND PEDIATRIC BRAIN CANCER AT SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING (PR Newswire)
Nov-02-22 07:10AM	Kazia Therapeutics (KZIA): Q123 Cash Flows in Line with Our Estimates (ACCESSWIRE) +5.68%
Oct-27-22 10:48AM	Kazia Therapeutics Reveals Paxalisib Preclinical Data In Melanoma Animal Models (Benzinga)
07:00AM	KAZIA'S PAXALISIB DEMONSTRATES POSITIVE MONOTHERAPY EFFICACY SIGNALS IN PRECLINICAL MODELS OF MELANOMA (PR Newswire)
Oct-06-22 08:00AM	PNOC CLINICAL STUDY OF KAZIA'S PAXALISIB IN CHILDHOOD BRAIN CANCER EXPANDS INTERNATIONALLY (PR Newswire) -11.48%
Sep-26-22 09:55AM	Novogen Limited (KZIA) Could Find Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Sep-09-22 08:00AM	KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT 24th ANNUAL GLOBAL INVESTMENT CONFERENCE (PR Newswire)
Sep-08-22 06:00PM	KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ESMO (PR Newswire)
Sep-07-22 10:35AM	Kazia Therapeutics (KZIA): Doubling Down on Clinical Development (ACCESSWIRE)
Aug-11-22 09:55AM	Here's Why Novogen Limited (KZIA) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Aug-05-22 10:00AM	Kazia Therapeutics Shares Jump On Interim Data From Paxalisib Combo Study In Brain Metastases (Benzinga)
08:40AM	KAZIA THERAPEUTICS REPORTS PROMISING INTERIM DATA FROM COMBINATION STUDY OF PAXALISIB WITH RADIOTHERAPY IN TREATMENT OF BRAIN METASTASES (PR Newswire)
Aug-01-22 07:00AM	Kazia Shares Tumble After Update From Pivotal Brain Tumor Trial (Benzinga) -47.11%
Jul-17-22 06:28PM	Kazia Therapeutics (ASX:KZA) Is In A Strong Position To Grow Its Business (Simply Wall St.)
Jul-12-22 08:15AM	KAZIA LAUNCHES NEW SCIENTIFIC ADVISORY BOARD COMPRISED OF WORLD-LEADING EXPERTS IN BRAIN CANCER (PR Newswire)
Jul-06-22 07:00AM	US FDA AWARDS RARE PEDIATRIC DISEASE DESIGNATION (RPDD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER (PR Newswire)
Jun-17-22 08:00AM	US FDA AWARDS ORPHAN DRUG DESIGNATION (ODD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER (PR Newswire)
Jun-13-22 07:00AM	POSITIVE DATA FOR PAXALISIB IN TWO CHILDHOOD BRAIN CANCERS PRESENTED AT 20TH ISPNO ANNUAL MEETING (PR Newswire) -5.47%
Jun-08-22 08:49PM	Quite a few insiders invested in Kazia Therapeutics Limited (ASX:KZA) last year which is positive news for shareholders (Simply Wall St.) +5.58%
Jun-07-22 07:00AM	PHASE II STUDY OF PAXALISIB IN BRAIN METASTASES ADVANCES TO EXPANSION STAGE IN BREAST CANCER BRAIN METASTASES COHORT (PR Newswire)
Jun-03-22 07:00AM	KAZIA PRESENTS POSITIVE FINAL DATA FROM PHASE II STUDY OF PAXALISIB IN NEWLY DIAGNOSED GLIOBLASTOMA AT ASCO CONFERENCE (PR Newswire)
May-31-22 07:00AM	GBM AGILE OPENS TO PAXALISIB IN EUROPE (PR Newswire)
May-26-22 07:50AM	Kazia Therapeutics (KZIA): Deep Dive Into Childhood Brain Cancer (ACCESSWIRE)
May-23-22 08:30AM	KAZIA THERAPEUTICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES HOSTED BY HC WAINWRIGHT AND LD MICRO (PR Newswire)
May-17-22 08:00AM	KAZIA MARKS DIPG AWARENESS DAY; NEW PRECLINICAL DATA IN DIPG TO BE PRESENTED AT ISPNO CONFERENCE (PR Newswire) +8.41%
May-16-22 09:12PM	Investing in Kazia Therapeutics (ASX:KZA) three years ago would have delivered you a 69% gain (Simply Wall St.)
Apr-29-22 11:00AM	KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ASCO (PR Newswire)
Apr-08-22 08:30AM	KAZIA THERAPEUTICS ANNOUNCES PRECLINICAL DATA PRESENTED AT AACR CONFERENCE BY JOHNS HOPKINS UNIVERSITY SHOWING ACTIVITY OF PAXALISIB IN PAEDIATRIC BRAIN TUMOURS (PR Newswire)
08:00AM	TWO ABSTRACTS AT AACR CONFERENCE PRESENT DETAILED STUDY DESIGN AND INNOVATIVE BIOMARKER STRATEGY FOR ONGOING PHASE I STUDY OF EVT801 IN ADVANCED CANCER (PR Newswire)
Mar-30-22 07:35AM	Kazia TherapeuticsTrust (KZIA): Several Upcoming Catalysts (ACCESSWIRE)
Mar-28-22 05:46AM	When Can We Expect A Profit From Kazia Therapeutics Limited (ASX:KZA)? (Simply Wall St.)
Mar-21-22 08:00AM	KAZIA TO PRESENT AT UPCOMING INVESTOR CONFERENCE AND AACR ANNUAL SCIENTIFIC MEETING (PR Newswire)
Feb-28-22 08:00AM	PHASE II CLINICAL STUDY AT WEILL CORNELL MEDICAL CENTER INVESTIGATING PAXALISIB IN COMBINATION WITH METFORMIN AND A KETOGENIC DIET ENROLLS FIRST PATIENT (PR Newswire)
Feb-07-22 02:25PM	We Think Kazia Therapeutics (ASX:KZA) Can Easily Afford To Drive Business Growth (Simply Wall St.) +6.53%
08:00AM	KAZIA THERAPEUTICS TO PRESENT AT BIO CEO CONFERENCE (PR Newswire)
Jan-25-22 08:00AM	KAZIA THERAPEUTICS TO PARTICIPATE IN EDISON GROUP'S GLOBAL HEALTHCARE 'OPEN HOUSE' VIRTUAL CONFERENCE (PR Newswire)
Jan-07-22 08:00AM	KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT BIOCONNECT CONFERENCE (PR Newswire)
Dec-24-21 02:33PM	Independent Non-Executive Director Steven Coffey Just Bought 12% More Shares In Kazia Therapeutics Limited (ASX:KZA) (Simply Wall St.)
Dec-13-21 11:00AM	KAZIA THERAPEUTICS APPOINTS KAREN KRUMEICH AS CHIEF FINANCIAL OFFICER (PR Newswire)
Dec-04-21 08:00AM	Kazia Announces Positive Final Data From Phase II Clinical Study Of Paxalisib In Newly Diagnosed Glioblastoma (PR Newswire)
Nov-29-21 08:00AM	GBM AGILE Opens to Paxalisib in Canada (PR Newswire)
Nov-28-21 09:47PM	Multiple insiders bought Kazia Therapeutics Limited (ASX:KZA) stock earlier this year, a positive sign for shareholders (Simply Wall St.)
Nov-15-21 11:00AM	Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer (PR Newswire)
Nov-11-21 08:00AM	PNOC Study in Childhood Brain Cancer Enrols First Patient (PR Newswire)
Nov-04-21 08:00AM	Kazia Enrols First Patient to EVT801 Phase I Clinical Trial (PR Newswire)
Nov-03-21 08:38PM	Kazia Enrols First Patient to EVT801 Phase I Clinical Trial (PR Newswire)
Oct-14-21 11:15AM	Kazia TherapeuticsTrust (KZIA): Multiple Paxalisib Data Points Expected in Q4 (ACCESSWIRE)
Oct-13-21 05:42PM	What Kind Of Investors Own Most Of Kazia Therapeutics Limited (ASX:KZA)? (Simply Wall St.)
Oct-06-21 10:00AM	Kazia Therapeutics to Present at LD Micro Main Event (PR Newswire)
Sep-10-21 12:30PM	Kazia Therapeutics to Present at HC Wainwright 23rd Annual Global Investment Conference (PR Newswire)
Sep-07-21 06:36PM	Investing in Kazia Therapeutics (ASX:KZA) three years ago would have delivered you a 241% gain (Simply Wall St.)
Aug-02-21 05:31PM	When Will Kazia Therapeutics Limited (ASX:KZA) Breakeven? (Simply Wall St.)
Jul-21-21 10:00AM	Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day (PR Newswire)
Jun-30-21 10:00AM	Kazia Provides Progress Update on Paxalisib and EVT801 Clinical Programs (PR Newswire)
Jun-16-21 03:36PM	How Many Kazia Therapeutics Limited (ASX:KZA) Shares Did Insiders Buy, In The Last Year? (Simply Wall St.)
Jun-15-21 10:00AM	Kazia Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma (PR Newswire)
Jun-07-21 08:00AM	Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient (PR Newswire)
Jun-03-21 07:00AM	Kazia Therapeutics to Present at LD Micro Invitational XI (PR Newswire)
May-02-21 07:52PM	Kazia Therapeutics (ASX:KZA) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Apr-30-21 08:00PM	The eggs files: why hens are at the centre of modern science (Financial Times)
Apr-20-21 11:35AM	Kazia Therapeutics (KZIA): New asset to target tumor lymphangiogenesis (ACCESSWIRE)
Apr-19-21 05:54AM	Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor, from Evotec SE (PR Newswire)
Mar-30-21 07:40AM	Kazia Therapeutics (KZIA): Paxalisib Chinese Rights Licensed (ACCESSWIRE) -6.38%
Mar-29-21 06:49AM	Kazia Therapeutics Stock Is Trading Higher On Paxalisib Licensing Agreement In Greater China (Benzinga) +15.65%
05:43AM	Kazia Licenses Rights to Paxalisib in Greater China to Simcere, a Leading Chinese Pharmaceutical Company (PR Newswire)
Mar-17-21 06:07PM	What Type Of Shareholders Own The Most Number of Kazia Therapeutics Limited (ASX:KZA) Shares? (Simply Wall St.)
Mar-01-21 06:00PM	Kazia Licenses Cantrixil, a Clinical-stage, First-in-class Ovarian Cancer Drug Candidate, to Oasmia Pharmacetical AB (PR Newswire) +5.01%
08:39AM	Kazia Therapeutics Licenses Cantrixil To Oasmia Pharmaceutical For Ovarian Cancer (Benzinga)
Jan-31-21 01:06PM	How Is Kazia Therapeutics' (ASX:KZA) CEO Paid Relative To Peers? (Simply Wall St.)
Jan-06-21 01:00PM	Global Coalition for Adaptive Research, Kazia, and Kintara Announce Commencement of Kazias Paxalisib and Kintaras VAL-083 in GBM AGILE Trial (Business Wire)

Kazia Therapeutics Ltd. is a clinical stage oncology company, which engages in the pharmaceutical research and development business. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KZIA

Kazia Therapeutics Limited ADR

Upgrade your FINVIZ experience